Long acting GLP-1 receptor agonist (injectable)
Taspoglutide 10 mg subcutaneous once weekly
TASP_SC_10MG_QW
Development discontinued.
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Type 2 diabetes (adults) | HbA1c change | weeks 20 to 36 (target week 26) | Placebo | MD -1.04 (-1.37 to -0.71) | 0.66 |
| Type 2 diabetes (adults) | HbA1c change | weeks 36 to 64 (target week 52) | Placebo | MD 0.39 (-0.09 to 0.89) | 0.25 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 36 to 64 (target week 52) | Placebo | MD -0.39 (-2.92 to 2.79) | 0.39 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 20 to 36 (target week 26) | Placebo | MD -0.98 (-2.25 to 0.28) | 0.59 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 0.24 (0.00 to 9.11) | 0.57 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 1.38 (0.71 to 2.62) | 0.51 |
| Type 2 diabetes (adults) | Systolic blood pressure change | weeks 20 to 36 (target week 26) | Placebo | MD -3.19 (-5.97 to -0.33) | 0.64 |
| Type 2 diabetes (adults) | Systolic blood pressure change | weeks 36 to 64 (target week 52) | Placebo | MD 3.85 (-1.82 to 9.46) | 0.41 |
| Type 2 diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 1.11 (0.72 to 1.71) | 0.42 |
| Type 2 diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 2.90 (1.47 to 5.88) | 0.30 |
| Type 2 diabetes (adults) | Nausea | longest follow-up | Placebo | HR 4.65 (3.19 to 6.62) | 0.27 |
| Type 2 diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 5.83 (3.68 to 9.22) | 0.25 |
| Type 2 diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 1.65 (1.13 to 2.47) | 0.49 |
| Type 2 diabetes (adults) | Constipation | longest follow-up | Placebo | HR 2.37 (1.16 to 4.88) | 0.35 |
| Type 2 diabetes (adults) | Discontinuation due to gastrointestinal adverse events | longest follow-up | Placebo | HR 2.45 (0.49 to 12.29) | 0.43 |
| Type 2 diabetes (adults) | Acute pancreatitis | longest follow-up | Placebo | HR 0.55 (0.04 to 6.49) | 0.56 |
Trials
- NCT00754988A Multicenter, Randomized, Double-dummy, Placebo and Active-controlled Study to Assess the Safety, Tolerability and Effect of Taspoglutide on Glycemic Control Compared to Sitagliptin and Placebo in Patients With Type II Diabetes Mellitus Inadequately Controlled With Metformin.2008 · 666 randomized · 156 weeks
- NCT00717457Randomized, Active Controlled, Open Label Study to Compare Taspoglutide vs Exenatide as add-on Treatment to Metformin and/or Thiazolidinediones in Patients With Type 2 Diabetes Mellitus2008 · 1,189 randomized · 52 weeks
- NCT00744926A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability and Effect of Taspoglutide Compared to Placebo, in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and Exercise2008 · 373 randomized · 24 weeks
- NCT00423501A Double Blind, Placebo-controlled, Dose-ranging Study to Investigate the Effect on Glycemic Control, Safety, Pharmacokinetics and Pharmacodynamics of GLP-1 in Patients With Type 2 Diabetes Mellitus Treated With a Stable Dose of Metformin.2007 · 306 randomized · 8 weeks